The US Food and Drug Administration’s Office of Tissues and Advanced Therapies is eyeing an internal reorganization, as well as changes in how it interacts with sponsors, to help it keep up with the burgeoning workload involving cell and gene therapies.
The tremendous growth in cell and gene therapy investigational new drug applications in recent years has necessitated a rethinking in...








